These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 20305699

  • 1. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.
    Mickelson DM, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, Copelan EA.
    Bone Marrow Transplant; 2011 Jan; 46(1):84-9. PubMed ID: 20305699
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW, Schmidt-Hieber M, Leschinger N, Göldner H, Knauf W, Hopfenmüller W, Thiel E, Blau O.
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [Abstract] [Full Text] [Related]

  • 4. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 5. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ.
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [Abstract] [Full Text] [Related]

  • 6. Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT.
    Cable C, Buzzeo MP, Schold JD, Khan S, Leather H, Moreb J, Jamieson K, Scornik J, Amdur RJ, Wingard JR, Reddy V.
    Bone Marrow Transplant; 2010 Jan; 45(1):31-7. PubMed ID: 19543325
    [Abstract] [Full Text] [Related]

  • 7. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, Takami A, Taniguchi S, Takemoto Y, Hara M, Yamaguchi M, Hino M, Yoshida T, Kim SW, Hori A, Ohashi Y, Takaue Y.
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [Abstract] [Full Text] [Related]

  • 8. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, Chung JS, Cho GJ, Yang DH, Lee JJ, Kim YK, Kim HJ.
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [Abstract] [Full Text] [Related]

  • 9. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS, Lee MS, Min CW, Park SK, Kim SH, Yun J, Kim HJ, Kim KH, Kim CK, Lee KT, Won JH, Hong DS.
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [Abstract] [Full Text] [Related]

  • 10. [Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].
    Bautista G, Regidor C, Gonzalo-Daganzo R, Cabrera JR.
    Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():47-51. PubMed ID: 21381288
    [Abstract] [Full Text] [Related]

  • 11. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
    Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, Lee JH, Lee WS, Park JH, Bae SH, Hyun MS, Kim DY, Kim SD, Min YJ, Lee KH.
    J Clin Oncol; 2013 Feb 20; 31(6):701-9. PubMed ID: 23129746
    [Abstract] [Full Text] [Related]

  • 12. Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience.
    Basara N, Roemer E, Kraut L, Guenzelmann S, Schmetzer B, Kiehl MG, Fauser AA.
    Bone Marrow Transplant; 2002 Nov 20; 30(10):651-9. PubMed ID: 12420203
    [Abstract] [Full Text] [Related]

  • 13. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct 20; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 14. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Körbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE.
    Bone Marrow Transplant; 2000 Sep 20; 26(6):615-20. PubMed ID: 11041566
    [Abstract] [Full Text] [Related]

  • 15. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
    Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C, Quinlan D, Stewart D.
    Biol Blood Marrow Transplant; 2007 Mar 20; 13(3):299-306. PubMed ID: 17317583
    [Abstract] [Full Text] [Related]

  • 16. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ, Lokhorst HL, Verdonck LF.
    Ned Tijdschr Geneeskd; 2003 Nov 22; 147(47):2328-32. PubMed ID: 14669540
    [Abstract] [Full Text] [Related]

  • 17. Cyclosporine levels and rate of graft rejection following non-myeloablative conditioning for allogeneic hematopoietic SCT.
    Gerull S, Arber C, Bucher C, Buser A, Gratwohl A, Halter J, Heim D, Tichelli A, Stern M.
    Bone Marrow Transplant; 2011 May 22; 46(5):740-6. PubMed ID: 20697371
    [Abstract] [Full Text] [Related]

  • 18. A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
    Shapira MY, Or R, Resnick IB, Bitan M, Ackerstein A, Samuel S, Elad S, Zilberman I, Miron S, Slavin S.
    Bone Marrow Transplant; 2003 Sep 22; 32(6):557-61. PubMed ID: 12953126
    [Abstract] [Full Text] [Related]

  • 19. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY, Choi MK, Kim DH, Kim SJ, Kim K, Kim WS, Chung CW, Kim HO, Min YH, Jang JH.
    Transplant Proc; 2010 Nov 22; 42(9):3723-8. PubMed ID: 21094846
    [Abstract] [Full Text] [Related]

  • 20. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S.
    Blood Cells Mol Dis; 2008 Nov 22; 40(1):48-54. PubMed ID: 17827036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.